CUTANEOUS HEAD AND NECK MELANOMA IN OPTIM, A RANDOMIZED PHASE III TRIAL OF TALIMOGENE LAHERPAREPVEC VERSUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF UNRESECTED STAGE

Tuesday, July 26, 2016